Drugs / DB-1419
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06554795 | Sep 2024 → Feb 2027 expected | cancer | DualityBio Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-09 | DualityBio Inc. | Regulatory DualityBio's Next-Generation Bispecific ADC DB-1419 Receives FDA IND Approval and Completes First Global Patient Dosing dualitybiologics.com ↗
DualityBio recently announced that its bispecific ADC drug DB-1419, developed based on its proprietary DIBAC platform, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) and a Clinical Trial Notification (CTN) from Australia's Therapeutic Goods Administration (TGA). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-09-09 | DualityBio Inc. | DualityBio's Next-Generation Bispecific ADC DB-1419 Receives FDA IND Approval and Completes First Global Patient Dosing dualitybiologics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DB-1419 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06554795 ↗ |
| Action | Deplete | “antibody-mediated antibody-dependent cellular cytotoxicity” PMID 40499141 ↗ Aug 2025 |
| Route | Intravenous | “Administered Injection of Vein (I.V.)” NCT06554795 ↗ |